Citadel Advisors
TTPH

Citadel Advisors’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Citadel Advisors’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,320
Closed -$122K – 7666
2016
Q1 		$122K Buy
1,320
+205
+18% +$20.5K ﹤0.01% 5937
2015
Q4 		$224K Buy
1,115
+480
+76% +$95.8K ﹤0.01% 5663
2015
Q3 		$95K Buy
635
+275
+76% +$202K ﹤0.01% 7008
2015
Q2 		$342K Buy
360
+225
+167% +$184K ﹤0.01% 5564
2015
Q1 		$99K Sell
135
-550
-80% -$413K ﹤0.01% 6849
2014
Q4 		$544K Buy
+685
New +$369K ﹤0.01% 4615

Other funds holding TTPH

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors's TTPH Position: Q3 2019 in Review

Citadel Advisors sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2019, closing a stake of 5,213 shares — an estimated $50K sold.

Citadel Advisors first reported a position in TTPH in Q1 2014 and held it in 17 quarters. The position peaked at $18.2M in Q2 2015. 26 funds tracked by Wall St. Rank hold TTPH as of Q3 2019.

  • Citadel Advisors reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Citadel Advisors sold 5,213 Tetraphase Pharmaceuticals, Inc. shares in Q3 2019, an estimated $50K.
  • Citadel Advisors first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2014 and held it in 17 quarters.
  • Citadel Advisors's Tetraphase Pharmaceuticals, Inc. position peaked at $18.2M in Q2 2015.
  • 26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2019.

Based on Citadel Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.